Penn Medicine Provider
Gynecologic Oncology
Robert L. Giuntoli, II, MD
5.0
(676)
Accepting new patients
Sees patients age 12 and up
Abramson Cancer Center West Chester
View 1 additional location
Make an appointmentCall 800-789-7366

About me

  • Medical Director of Surgical Oncology at Penn Medicine Chester County Hospital
  • Director of Gynecologic Oncology Penn Medicine Chester County Hospital
  • Professor of Clinical Obstetrics and Gynecology

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Duke University Medical Center
  • Fellowship: Women & Infant's Hospital of Rhode Island
  • Fellowship: Mayo Clinic

What my patients think about me

Average Rating
5.0

676 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
excellent care
May 2025
5.0
5.0
he answered my questions and asked if there were any other concerns
May 2025
5.0
5.0
answers my questions
May 2025
5.0
5.0
he is very knowledgeable and has amazing bedside manner

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Giuntoli is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Nasioudis D, Labban N, Gysler S, Ko EM, Giuntoli RL 2nd, Kim SH, Latif NA Outcomes of Radical Hysterectomy for Early-Stage Cervical Carcinoma, with or without Prior Cervical Excision Procedure. , Cancers (Basel), 16(11):2051: 2024

Nasioudis D, Gysler S, Latif NA, Giuntoli RL 2nd, Kim SH, Ko EM Role of systematic lymphadenectomy at the time of interval debulking surgery for patients with advanced-stage epithelial ovarian carcinoma who achieved complete gross resection. , Int J Gynecol Cancer, 34(7):969-974: 2024

Nasioudis D, Gysler S, Latif N, Cory L, Giuntoli RL 2nd, Kim SH, Simpkins F, Martin L, Ko EM Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. , Gynecol Oncol, 180:1-5: 2024

Nasioudis D, Wang X, Dhillon G, Latif N, Ko EM, Giuntoli RL 2nd, Gershenson D, Fader A, Carey M, Simpkins F Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. , Int J Gynecol Cancer: 2023,33(12):1906-1912

Nasioudis D, Arevalo O, Gysler S, Ko EM, Cory L, Kim SH, Giuntoli RL 2nd, Latif NA Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma. , Int J Gynecol Cancer, ijgc-2023-004805: 2023

Nasioudis D, Latif NA, Ko EM, Cory L, Kim SH, Martin L, Simpkins F, Giuntoli R 2nd Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. , Gynecol Oncol, 177:14-19: 2023

Nasioudis D, Labban N, Latif N, Gysler S, Cory L, Kim S, Giuntoli RL 2nd, Ko EM Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes. , Int J Gynecol Cancer, 33(9):1347-1353: 2023

Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer. , Clin Cancer Res, 29(15):2800-2807: 2023

Nasioudis D, Gysler S, Latif N, Ko E, Cory L, Giuntoli II RL, Kim S, Simpkins F Molecular profiling of mucinous ovarian carcinoma reveals actionable mutations and a unique genomic profile. , (Poster) 54th Society of Gynecologic Oncology annual meeting, Tampa, FL: 2023

Nasioudis D, Gysler S, Latif N, Ko E, Cory L, Giuntoli R, Kim S, Simpkins F Prevalence of ESR1 gene mutations in gynecologic malignancies with high-estrogen receptor expression. , (Poster) 54th Society of Gynecologic Oncology annual meeting, Tampa, FL: 2023